GlassScriptPhysician profile
Stanley P Watkins
NPI 1548294945
$6,741.38
in general payments reported to CMS, 2019-2025
26 companies · $907 in 2025
The $907 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $682 · 2021: $491 · 2022: $602 · 2023: $1,147 · 2024: $604 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,618.00 | 2019-2025 | Mitraclip, Triclip, Coroflow |
| Edwards Lifesciences Corporation | $886.01 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $610.38 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $552.21 | 2019-2024 | Stingray, Avvigo Guidance System, Embold Fibered |
| E.R. Squibb & Sons, L.L.C. | $414.91 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $292.31 | 2020-2025 | Impella |
| W. L. Gore & Associates, INC. | $167.70 | 2019-2021 | |
| Amgen INC. | $150.44 | 2019-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $120.80 | 2025 | Uptravi, Opsumit |
| Philips North America LLC | $118.31 | 2019-2021 | |
| Penumbra, INC. | $109.55 | 2020-2023 | Benchmark |
| Novartis Pharmaceuticals Corporation | $101.49 | 2019-2023 | |
| Medtronic Vascular, INC. | $99.10 | 2019 | |
| Cardiovascular Systems INC. | $78.11 | 2019-2023 | Diamondback Coronary |
| Cardiva Medical, INC. | $76.22 | 2025 | Savvywire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $59.92 | 2019-2023 | Orsiro Mission |
| Astrazeneca Pharmaceuticals LP | $58.45 | 2019 | |
| Ethicon US, LLC | $43.28 | 2022 | |
| Atricure, INC. | $41.71 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.23 | 2019-2021 | |
| Teleflex LLC | $26.69 | 2019-2023 | Guideliner |
| Chiesi USA, INC. | $22.22 | 2019 | |
| Siemens Medical Solutions USA, INC. | $18.68 | 2021 | |
| Merck Sharp & Dohme LLC | $17.09 | 2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $16.60 | 2019 | |
| Pfizer INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.